Anthem Biosciences
Anthem Biosciences, a leading biotechnology firm headquartered in India, has established itself as a key player in the life sciences industry since its inception in 2009. With a strong operational presence across various regions, the company focuses on providing innovative solutions in drug discovery, development, and manufacturing. Specialising in custom biologics, Anthem Biosciences offers a range of services, including monoclonal antibody development and protein expression systems. Their commitment to quality and efficiency sets them apart in a competitive market. Over the years, the company has achieved significant milestones, enhancing its reputation for excellence in biopharmaceutical services. Recognised for its cutting-edge technologies and robust client partnerships, Anthem Biosciences continues to drive advancements in the biotechnology sector, positioning itself as a trusted partner for pharmaceutical and biotech companies worldwide.
DitchCarbon Score
How does Anthem Biosciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Anthem Biosciences's score of 15 is lower than 79% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Anthem Biosciences's reported carbon emissions
In 2023, Anthem Biosciences reported total carbon emissions of approximately 12,650,000 kg CO2e. This figure includes 10,798,000 kg CO2e from Scope 1 emissions, which are direct emissions from owned or controlled sources, and 2,355,000 kg CO2e from Scope 2 emissions, representing indirect emissions from the generation of purchased electricity, steam, heating, and cooling. Additionally, the company recorded 33,000 kg CO2e in Scope 3 emissions, which encompass all other indirect emissions that occur in the value chain. For 2024, emissions increased to about 17,631,000 kg CO2e, with Scope 1 emissions rising to 13,561,000 kg CO2e and Scope 2 emissions to 3,923,000 kg CO2e, while Scope 3 emissions increased to 147,000 kg CO2e. Anthem Biosciences has committed to near-term climate targets, although specific reduction targets have not been disclosed. The company has not yet committed to a net-zero target. As a player in the Pharmaceuticals, Biotechnology, and Life Sciences sector, Anthem is actively working towards improving its sustainability practices in line with industry standards.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 10,798,000 | 00,000,000 |
| Scope 2 | 2,355,000 | 0,000,000 |
| Scope 3 | 33,000 | 000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Anthem Biosciences is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
